The review, led by researchers surveying the state of the art in wearable, implantable, biodegradable and self-powered biosensing platforms, takes an unusually rigorous approach. Rather than simply cataloguing recent breakthroughs, the authors analysed 144 publications using a bibliometric method, building a quantitative map of the research landscape. The analysis reveals a field that has grown rapidly and become deeply multidisciplinary, drawing on electrochemistry, materials science, microfluidics, wireless engineering and data science. It also charts a decisive transition in ambition: from one-off or periodic measurements toward connected, autonomous sensors that operate reliably for weeks, months or even longer.

At the heart of this transformation lies a quiet revolution in materials. The review systematically examines how advanced functional materials are being engineered to overcome the classic weaknesses of biosensors, which historically traded sensitivity for stability and speed for selectivity. Carbon nanotubes and graphene quantum dots, with their extraordinary electrical conductivity and vast surface areas, enhance charge transfer between the biological recognition element and the electronic transducer, boosting signal strength. MXenes, a family of two-dimensional transition metal carbides and nitrides, and covalent organic frameworks, crystalline porous polymers with tunable chemistry, create pathways that improve analyte accessibility, allowing target molecules to reach the sensing surface more efficiently even in complex samples.

Perhaps most intriguing are the materials designed to solve the selectivity problem, arguably the hardest challenge in biosensing. Molecularly imprinted polymers act as artificial antibodies, with binding cavities sculpted around a template molecule during synthesis, giving them the ability to recognise specific targets amid a crowded biochemical background. Functional polymers and hydrogels add reversible recognition, meaning the sensor surface can release the analyte and be regenerated for the next measurement cycle, a property essential for any device intended to monitor continuously rather than be used once. Chiral composites exploit the handedness of molecules to discriminate between chemically identical mirror-image forms, a subtle but clinically important distinction, while engineered antifouling surfaces resist the protein and cell deposition that would otherwise blind the sensor within hours of deployment.

On the mechanical side, hydrogels and flexible polymers allow devices to conform to the curved, moving surfaces of the human body, maintaining stable contact with skin or tissue without irritation. This mechanical flexibility, combined with biocompatible encapsulation and, in some designs, fully biodegradable architectures, is what turns a laboratory curiosity into a device a patient can genuinely live with. Self-powered designs go further, harvesting energy from bodily motion or bioelectrochemical reactions to eliminate the need for battery replacement, a major barrier for implantables.

The review is careful to stress that materials alone do not make a continuous monitoring system. Electrochemical and optical transduction strategies are examined systematically, since the choice of how a molecular binding event is converted into an electrical or optical signal determines much of the device’s performance envelope. Around that core, the modern biosensor is increasingly a networked computing device. Microfluidic channels deliver and prepare samples at microscopic scales, wireless links transmit data from body or field, and artificial intelligence and machine learning algorithms interpret raw signals, compensate for drift and extract clinically meaningful trends. Edge and cloud computing architectures, tied together through the Internet of Things, are enabling multiplexed platforms that track many biomarkers simultaneously and even close the loop, adjusting a therapy automatically in response to what the sensor measures.

Yet the review’s most sobering contribution may be its honest assessment of the barriers standing between laboratory promise and real-world deployment. Sensor regeneration, the ability to reset the sensing surface without degrading it, remains difficult. Biofouling, the accumulation of biological material on the device, degrades signal quality over time. Signal drift means a sensor calibrated on day one may report falsely by day ten, and matrix interference from proteins, salts and other sample components can swamp the target signal entirely. Calibration strategies, energy demands, biocompatibility, device integration, manufacturing scalability, cybersecurity of connected health devices, regulatory compliance and the scarcity of genuine clinical and field validation all loom as obstacles that laboratory benchmarks routinely understate.

Indeed, one of the review’s most striking arguments is that the traditional figures of merit of analytical chemistry, sensitivity and limit of detection, are simply inadequate for judging whether a biosensor is ready for deployment. A device can post dazzling detection limits in a clean buffer solution and still fail within days in blood, sweat or river water. What matters instead, the authors contend, are long-term stability, tolerance of complex matrices, reproducibility between devices and validation under realistic conditions. Until the field adopts these deployment-oriented metrics alongside conventional ones, lab-to-life translation will remain the exception rather than the rule.

The path forward, as the review sketches it, is correspondingly holistic. Priority directions include regenerative and antifouling sensing interfaces that keep themselves clean and functional, multimodal and self-powered platforms that reduce dependency on external energy, physiomimetic and minimally invasive architectures that the body tolerates better, and AI-enabled signal interpretation that can distinguish true biological trends from artefacts. Equally critical are unglamorous but essential steps: standardized performance metrics that allow honest comparison between devices, scalable manufacturing routes that can bring costs down, and rigorous clinical and environmental validation studies that test devices where they will actually be used.

Taken together, the review’s message is that reliable continuous biosensing will not emerge from any single breakthrough in nanomaterials or transduction chemistry. It demands the coordinated advancement of advanced materials, biorecognition chemistry, device engineering, energy management, digital connectivity and data analytics as an integrated system. If that integration succeeds, the payoff is substantial: personalized healthcare that watches over patients continuously rather than at the discretion of a blood draw schedule, and environmental stewardship that detects contamination as it happens rather than after the fact. The sensors are getting closer to ready. The challenge now is everything around them.

Subject of Research: Continuous monitoring biosensors for healthcare and environmental applications

Article Title: Continuous monitoring biosensors for advanced healthcare and environmental applications: challenges, material innovations and future directions

Article References: Amireddy, K. K., Reddy, P. V. R. R., Reddy, C. N., & Reddy, P. P. (2026). Continuous monitoring biosensors for advanced healthcare and environmental applications: challenges, material innovations and future directions. Frontiers in Sensors, 7, Article 1968999. https://doi.org/10.3389/fsens.2026.1968999

Image Credits: AI Generated

DOI: 10.3389/fsens.2026.1968999

Keywords: biosensors, continuous monitoring, wearables, implantable sensors, MXenes, graphene quantum dots, molecularly imprinted polymers, hydrogels, electrochemical sensors, artificial intelligence, Internet of Things, environmental monitoring